WHO predicts 30M deaths from cancer globally by 2040, up from 18M in 2018. This is equivalent to almost half the British population.

We need this blood test across the UK. It’s saved my life, and everyone should have it. It will save so many lives.

Rebecca
Glasgow, Scotland

Cancer drug trials using biomarkers are 6.7 times more likely to be approved for use.

Today, only 12% of cancer patients in the US benefit from the transformative, approved immunotherapies.

I couldn't believe it when they told me I had lung cancer. I was out of hospital just a week after the operation.

Wilma
Wishaw, Scotland

We understand disease through the lens of the human immune system, to enable early detection and better treatment of cancer.

Events

View all

Proactive One2One Biotech Forum

Oncimmune CEO, Dr Adam M Hill will present progress on the Company's three year strategy.

Event—30 Jul 2020

Presentation at the Shares & AJ Bell Investor Evening - webinar

Shares Spotlight webinars feature presentations from directors of listed companies explaining their investment propositions followed by an opportunity for attendees to ask questions.

Event—08 Jul 2020

ASCO Virtual Scientific Program 2020

Professor Jessica Hassel presents findings from 'Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasised melanoma'

Event—29 May 2020

Proactive One2One Biotech Forum

Oncimmune CEO, Dr Adam M Hill will present progress on the Company's three year strategy.

Event—30 Jul 2020

Presentation at the Shares & AJ Bell Investor Evening - webinar

Shares Spotlight webinars feature presentations from directors of listed companies explaining their investment propositions followed by an opportunity for attendees to ask questions.

Event—08 Jul 2020

ASCO Virtual Scientific Program 2020

Professor Jessica Hassel presents findings from 'Autoantibodies as predictors for survival and immune-related adverse events in checkpoint inhibition therapy of metastasised melanoma'

Event—29 May 2020

Extra Time

Event
—
10 Feb 2020

Extra Time exhibition

10 Feb 2020

Portraits of hope and survival from lung cancer detection.

We want to detect lung cancer early and give many more people the chance to be treated successfully and to live longer. It is inequitable that only those who were lucky enough to be invited to take part in the ECLS trial and who are featured in this exhibition, were given that chance. Thousands more deserve to be given extra time.

Event

Latest

@OncimmuneECDT

Presentation at the Shares & AJ Bell Investor Evening - webinar

Shares Spotlight webinars feature presentations from directors of listed companies explaining their investment propositions followed by an opportunity for attendees to ask questions.

Event—08 Jul 2020

@OncimmuneECDT

EarlyCDT Lung blood test receives marketing authorisation for the early detection of lung cancer in Brazil

Open external link

Tweet—05 Jul 2020

EarlyCDT Lung for cancer risk classification of indeterminate pulmonary nodules.

NICE Medtech Innovation Briefing on EarlyCDT Lung

Open external link

Publication—17 Mar 2020

@OncimmuneECDT

"SMALL CAP SHARE IDEAS: Oncimmune highlights the resurgence of Britain's biotech sector during the pandemic"

Open external link

Tweet—07 Jul 2020

@OncimmuneECDT

“I didn’t have a cough. I could walk for miles. I had none of the signs. The test showed I had #cancer and I was offered an operation. They removed the cancer and a bit of my left lung. It saved my life."

Open external link

Tweet—06 Jul 2020

Diagnostics: why are they now getting the attention they deserve?

Article—10 May 2020

@OncimmuneECDT

EarlyCDT Lung blood test receives marketing authorisation for the early detection of lung cancer in Brazil

Open external link

Tweet—05 Jul 2020

@OncimmuneECDT

“I didn’t have a cough. I could walk for miles. I had none of the signs. The test showed I had #cancer and I was offered an operation. They removed the cancer and a bit of my left lung. It saved my life."

Open external link

Tweet—06 Jul 2020

@OncimmuneECDT

Experts call for lung cancer test after successful trials in Scotland

Open external link

Tweet—05 Jul 2020

Has this doctor revolutionised lung cancer detection?

Article—02 Nov 2019

EarlyCDT Lung for cancer risk classification of indeterminate pulmonary nodules.

NICE Medtech Innovation Briefing on EarlyCDT Lung

Open external link

Publication—17 Mar 2020

Oncimmune submission to Health and Social Care Committee inquiry

Article—29 Jan 2020

Presentation at the Shares & AJ Bell Investor Evening - webinar

Shares Spotlight webinars feature presentations from directors of listed companies explaining their investment propositions followed by an opportunity for attendees to ask questions.

Event—08 Jul 2020

@OncimmuneECDT

"SMALL CAP SHARE IDEAS: Oncimmune highlights the resurgence of Britain's biotech sector during the pandemic"

Open external link

Tweet—07 Jul 2020